Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 9/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505506 | 0.78 | PLK1 (0.36) | PLK1PLK3CDK2IKBKEOPRM1 | |
| SCHEMBL2502716 | 0.73 | PLK1 (0.44) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL2502714 | 0.72 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEOPRM1 | |
| SCHEMBL5249932 | 0.71 | PLK1 (0.39) | PLK1GRM6PLK3CDK2IKBKE | |
| SCHEMBL5141391 | 0.71 | PLK1 (0.39) | PLK1GRM6PLK3CDK2IKBKE | |
| SCHEMBL2494456 | 0.71 | PLK1 (0.41) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL2494455 | 0.71 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEOPRM1 | |
| SCHEMBL2504743 | 0.71 | KMT2A (0.44) | PLK1PLK3CDK2IKBKEOPRM1 | |
| SCHEMBL2505508 | 0.69 | PLK1 (0.35) | PLK1PLK3CDK2IKBKEOPRM1 | |
| SCHEMBL3156557 | 0.68 | PLK1 (0.35) | PLK1PLK3CDK2IKBKECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | PLK1 4301/4885GRM6 2221/4885PLK3 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.